Sumary of Pfizer to allow generic versions of its COVID-19 pill in 95 countries:
- Pfizer Inc said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low— and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).
- The voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified generic drug manufacturers to make their own versions of PF-07321332. Pfizer will sell the pills it manufactures under the brand name Paxlovid.
- Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, has said the pill cut the chance of hospitalization or death for adults at risk of severe disease by 89% in its clinical trial.
- Pfizer’s licensing deal follows a similar arrangement by rival Merck &
- “We are extremely pleased to have another weapon in our armory to protect people from the ravages of COVID-19,” Charles Gore, Executive Director of the Medicines Patent Pool, said in an interview.
- Gore said he hoped the generic version of Pfizer’s drug will be available within months.
- They also include countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said.
- “We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections… We must work to ensure that all people — regardless of where they live or their circumstances — have access to these breakthroughs,” Pfizer Chief Executive Albert Bourla said in a statement.